Covid 19 Research using Clinical Trials (Home Page)
Convalescent PlasmaWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (9)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug765 | Standard Plasma Wiki | 0.35 |
| drug763 | Standard Donor Plasma Wiki | 0.35 |
| drug859 | Tradipitant Wiki | 0.35 |
| drug921 | all treatment about COVID-2019 Wiki | 0.35 |
| drug680 | Rapid diagnostics using Anyplex TMII RV16 Detection Wiki | 0.35 |
| drug457 | Lactated ringer's solution or sterile saline Wiki | 0.35 |
| drug895 | Video based aerobic exercise Wiki | 0.35 |
| drug254 | Delayed diagnostics Anyplex TMII RV16 Detection Wiki | 0.35 |
| drug616 | Placebo Wiki | 0.04 |
Correlated MeSH Terms (10)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005335 | Fever of Unknown Origin NIH | 0.35 |
| D002637 | Chest Pain NIH | 0.35 |
| D004417 | Dyspnea NIH | 0.20 |
| D004630 | Emergencies NIH | 0.12 |
| D002318 | Cardiovascular Diseases NIH | 0.11 |
| D018352 | Coronavirus Infections NIH | 0.10 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D014777 | Virus Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100749 | Chest pain HPO | 0.35 |
| HP:0002098 | Respiratory distress HPO | 0.25 |
There are 8 clinical trials
Clinical Trials
1 Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19
Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19.
NCT04325672 Coronavirus Biological: Convalescent Plasma MeSH:Coronavirus Infections
Primary Outcomes
Description: Change in RNA levels of SARS-CoV-2 from nasopharyngeal using RT-PCR (reverse transcriptase polymerase chain reaction) across time.
Measure: RNA in SARS-CoV-2 Time: Days 0, 1, 3, 7, 14, 28, 60 and 90 after transfusionDescription: Total number of subjects to be admitted to the ICU after the anti-SARS-CoV-2 convalescent plasma transfusion.
Measure: ICU Admissions Time: 90 days after transfusionDescription: Total number of subject deaths.
Measure: Hospital Mortality Time: 90 days after transfusionDescription: The total number of days subjects were admitted to the hospital.
Measure: Hospital Length of Stay (LOS) Time: 90 days after transfusionSecondary Outcomes
Description: The type of supplemental oxygen support (e.g. nasal cannula, high flow nasal cannula, noninvasive ventilation, intubation and invasive mechanical ventilation, rescue ventilation) of the anti-SARS-CoV-2 convalescent plasma group across time.
Measure: Type of respiratory support Time: 90 days after transfusion or until hospital discharge (whichever comes first)Description: The total number of days subjects required respiratory support.
Measure: Duration of respiratory support Time: 90 days after transfusion or until hospital discharge (whichever comes first)2 Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
Coronavirus disease 2019 (COVID-19) was recognized as a pandemic on March 11, 2020 by the World Health Organization. The virus that causes COVID-19 (SARS-CoV-2) is easily transmitted through person to person and there is still no specific approach against the disease and mortality rate in severe cases is also significant. Therefore, finding effective treatment for the mortality of these patients is very important. In this study the investigators aim to determine the effect of Convalescent Plasma on COVID-19 patients Outcome through a Clinical Trial
NCT04327349 Coronavirus Infections Biological: Convalescent Plasma MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome
Primary Outcomes
Description: Measure of the number of deaths in a particular population, scaled to the size of that population, per unit of time.
Measure: Mortality changes in day 10 Time: 10 days after plasma transmissionDescription: Measure of the number of deaths in a particular population, scaled to the size of that population, per unit of time.
Measure: Mortality changes in day 30 Time: 30 days after plasma transmissionDescription: Measurement of CRP
Measure: Changes of C-reactive protein Time: Day 1Description: Measurement of CRP
Measure: Changes of C-reactive protein Time: Day 3Description: Measurement of CRP
Measure: Changes of C-reactive protein Time: Day 7Description: Measurement of IL-6
Measure: Changes of Interleukin 6 Time: Day 1Description: Measurement of IL-6
Measure: Changes of Interleukin 6 Time: Day 3Description: Measurement of IL-6
Measure: Changes of Interleukin 6 Time: Day 7Description: Measurement of TNF-α
Measure: Changes of tumor necrosis factor-α Time: Day 1Description: Measurement of TNF-α
Measure: Changes of tumor necrosis factor-α Time: Day 3Description: Measurement of TNF-α
Measure: Changes of tumor necrosis factor-α Time: Day 7Description: Partial pressure of arterial oxygen/Percentage of inspired oxygen
Measure: Changes of PaO2/FiO2 Ratio Time: Day 1Description: Partial pressure of arterial oxygen/Percentage of inspired oxygen
Measure: Changes of PaO2/FiO2 Ratio Time: Day 3Description: Partial pressure of arterial oxygen/Percentage of inspired oxygen
Measure: Changes of PaO2/FiO2 Ratio Time: Day 7Secondary Outcomes
Measure: Changes of CD3 Time: Day 1Measure: Changes of CD3 Time: Day 3
Measure: Changes of CD3 Time: Day 7
Measure: Changes of CD4 Time: Day 1
Measure: Changes of CD4 Time: Day 3
Measure: Changes of CD4 Time: Day 7
Measure: Changes of CD8 Time: Day 1
Measure: Changes of CD8 Time: Day 3
Measure: Changes of CD8 Time: Day 7
Measure: Changes of CD4/CD8 ratio Time: Day 1
Measure: Changes of CD4/CD8 ratio Time: Day 3
Measure: Changes of CD4/CD8 ratio Time: Day 7
Measure: Changes of lymphocyte count Time: Day 1
Measure: Changes of lymphocyte count Time: Day 3
Measure: Changes of lymphocyte count Time: Day 7
Measure: Changes of leukocyte count Time: Day 1
Measure: Changes of leukocyte count Time: Day 3
Measure: Changes of leukocyte count Time: Day 7
Measure: Changes of alanine transaminase (ALT) Time: Day 1
Measure: Changes of alanine transaminase (ALT) Time: Day 3
Measure: Changes of alanine transaminase (ALT) Time: Day 7
Measure: Changes of aspartate transaminase (AST) Time: Day 1
Measure: Changes of aspartate transaminase (AST) Time: Day 3
Measure: Changes of aspartate transaminase (AST) Time: Day 7
Measure: Changes of alkaline phosphatase (ALP) Time: Day 1
Measure: Changes of alkaline phosphatase (ALP) Time: Day 3
Measure: Changes of alkaline phosphatase (ALP) Time: Day 7
Measure: Changes of lactate dehydrogenase (LDH) Time: Day 1
Measure: Changes of lactate dehydrogenase (LDH) Time: Day 3
Measure: Changes of lactate dehydrogenase (LDH) Time: Day 7
Measure: Changes of creatine phosphokinase (CPK) Time: Day 1
Measure: Changes of creatine phosphokinase (CPK) Time: Day 3
Measure: Changes of creatine phosphokinase (CPK) Time: Day 7
Measure: Changes of Creatine kinase-MB (CK-MB) Time: Day 1
Measure: Changes of Creatine kinase-MB (CK-MB) Time: Day 3
Measure: Changes of Creatine kinase-MB (CK-MB) Time: Day 7
Measure: Changes of Specific IgG Time: Day 1
Measure: Changes of Specific IgG Time: Day 3
Measure: Changes of Specific IgG Time: Day 7
Description: Computed tomography Scan and Chest X-Ray
Measure: Radiological findings Time: Within 2 hours after admissionDescription: Computed tomography Scan and Chest X-Ray
Measure: Radiological findings Time: Day 14Measure: Number of days ventilated Time: Through study completion, an average of 2 weeks
Measure: Length of hospitalization Time: Through study completion, an average of 2 weeks
3 Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection
There is currently no specific vaccine or treatment to treat critically ill patients with COVID-19. Different therapies are still under investigation and are use in different health institutions, however, a significant proportion of patients do not respond to these treatments, so it is important to seek new treatments. One of these alternatives is the use of convalescent plasma. The investigator will use plasma obtained from convalescent individuals with proven novel SARS-CoV-2 virus infection, diagnosed with coronavirus-19-induced disease and symptom-free for a period of not less than 10 days since they recovered from the disease. This plasma will be infused in patients affected by the same virus, but who have developed respiratory complications that have not responded favorably to usual treatment such as chloroquine, hydroxychloroquine, azithromycin, and other antivirals. The investigator will evaluate the safety of this procedure by accounting for any adverse event.
NCT04333355 COVID-19 Biological: Convalescent Plasma
Primary Outcomes
Description: Identify possible adverse effects after the administration of convalescent plasma
Measure: Side effects Time: 14 daysSecondary Outcomes
Description: Development of heart failure during convalescent plasma transfusion or after it.
Measure: Heart Failure Time: 14 daysDescription: Development of pulmonary edema during convalescent plasma transfusion or after it.
Measure: Pulmonary Edema Time: 14 daysDescription: Development of any allergic reaction during convalescent plasma transfusion or after it.
Measure: Allergic Reaction Time: 14 daysDescription: Thorax Computer tomography
Measure: Lung infiltrates Time: 48 hoursDescription: Thorax Computer tomography
Measure: Lung infiltrates Time: 14 daysDescription: RT PCR SARS-CoV-2
Measure: Viral load of SARS-CoV-2 Time: 48 hrsDescription: RT PCR SARS-CoV-2
Measure: Viral load of SARS-CoV-2 Time: 14 days4 Convalescent Plasma in the Treatment of COVID 19
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
NCT04343261 SARS-CoV-2 COVID Coronavirus Biological: Convalescent Plasma MeSH:Coronavirus Infections
Primary Outcomes
Description: Mortality within 28 days
Measure: Mortality Time: 28 daysDescription: Reduction of Viral Load ]
Measure: Viral Load Time: 7 daysDescription: Change in Serum Antibody Titers
Measure: Serum Antibody Titers Time: 7 days5 Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection
The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Antibodies are blood proteins produced by the body in response to a virus and can remain in the person's bloodstream (plasma) for a long time after they recover. Transferring plasma from a person who recovered from COVID-19 may help neutralize the virus in sick patients' blood, and/or reduce the chances of the infection getting worse.
NCT04344535 COVID Biological: Convalescent Plasma Biological: Standard Donor Plasma
Primary Outcomes
Description: Number of days a patient is receiving mechanical invasive ventilation through 28 days post randomization. Patients who die during this time period are assigned 0 ventilator free days.
Measure: 28 day ventilator free days Time: 28 days post randomizationSecondary Outcomes
Description: All cause mortality from randomization until 90 days post randomization
Measure: 90 day all-cause mortality Time: 90 days6 Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Double-Blind, Phase 2 Study Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Placebo in Emergency Room Patients
This study will evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma (convalescent plasma) versus control (standard plasma) in patients with COVID-19 respiratory symptoms. This study will recruit patients who present for clinical evaluation in the emergency department (ED) but who do not require hospital admission. Disease progression due to COVID-19 will be assessed, which may include changes in symptom severity, return visit to the ED, or hospital admission.
NCT04355767 COVID-19 Biological: Convalescent Plasma Biological: Standard Plasma MeSH:Emergencies
Primary Outcomes
Description: Progression of disease is defined as any of the following: Patient admitted to the hospital Patient seen in the emergency room (return visit after visit when enrollment takes place) Patient reports increased symptoms of 2 levels on the COVID Outpatient Ordinal Outcomes Scale over a 24 hour period Patient reports increased symptoms of 1 level on the COVID Outpatient Ordinal Outcomes Scale observed for a 48 hour period. COVID Outpatient Ordinal Outcomes Scale: Patient requires care in the hospital Patient requires care in the ED or urgent care Patient at home with symptoms rates as moderate (defined as fever, shortness of breath, abdominal pain) Patient at home with symptoms rated as mild (defined as afebrile, constitutional symptoms (flu-like illness) without shortness of breath) Patient in their usual state of health
Measure: Time to disease progression Time: 15 daysSecondary Outcomes
Description: Categorical change in symptom severity rated on the COVID Outpatient Ordinal Outcomes Scale: Patient requires care in the hospital Patient requires care in the ED or urgent care Patient at home with symptoms rates as moderate (defined as fever, shortness of breath, abdominal pain) Patient at home with symptoms rated as mild (defined as afebrile, constitutional symptoms (flu-like illness) without shortness of breath) Patient in their usual state of health
Measure: Change in symptom severity over time Time: 15 days7 Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program
This is an expanded access treatment protocol to treat up to 100 patients with severe or life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma.
NCT04363034 COVID-19 Biological: Convalescent Plasma
8 Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
NCT04364737 COVID-19 Coronavirus Coronavirus Infection Biological: Convalescent Plasma Biological: Lactated ringer's solution or sterile saline MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome
Primary Outcomes
Description: No clinical or virological evidence of infection Not hospitalized, no limitations on activities Not hospitalized, limitation on activities Hospitalized, not requiring supplemental oxygen Hospitalized, requiring supplemental oxygen Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, on invasive mechanical ventilation or ECMO Death
Measure: Percentage of subjects reporting each severity rating on WHO ordinal scale for clinical improvement Time: 14 days post randomizationSecondary Outcomes
Description: No clinical or virological evidence of infection Not hospitalized, no limitations on activities Not hospitalized, limitation on activities Hospitalized, not requiring supplemental oxygen Hospitalized, requiring supplemental oxygen Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, on invasive mechanical ventilation or ECMO Death
Measure: Percentage of subjects reporting each severity rating on WHO ordinal scale for clinical improvement Time: 28 days post randomizationOther Outcomes
Description: Anti-SARS-CoV-2 titers (IgM, IgG, IgA)
Measure: Comparison in Anti-SARS-CoV-2 antibody titers Time: 0, 1, 7, 14, 28, 90 days post randomizationDescription: SARS-CoV-2 PCR in nasopharyngeal swabs
Measure: Proportion positive in SARS-CoV-2 RNA Time: 0, 7, 14, 28 days post randomizationDescription: Rate of mortality
Measure: Mortality Time: 7, 14, 28 days post randomizationDescription: Percentage of patients requiring Intensive Care Unit admission
Measure: Rates of Intensive Care Unit admission Time: 7, 14, 28 days post randomizationDescription: Lymphocyte counts
Measure: Changes from baseline in lymphocyte Time: 0, 1, 3, 7, 14 days post randomizationDescription: Neutrophil counts
Measure: Changes from baseline in neutrophils Time: 0, 1, 3, 7, 14 days post randomizationDescription: D-dimer level
Measure: Changes from baseline in D-dimer Time: 0, 1, 3, 7, 14 days post randomizationDescription: Fibrinogen level
Measure: Changes from baseline in fibrinogen Time: 0, 1, 3, 7, 14 days post randomizationDescription: T cell subsets
Measure: Changes from baseline in T lymphocyte subsets Time: 0, 7, 28 days post randomizationDescription: B cell subsets
Measure: Changes from baseline in B lymphocyte subsets Time: 0, 1, 3, 7, 14 days post randomization